Programs promoting timely sequential antimicrobial therapy: An American perspective

Journal of Infection

Volumn 37, Issue SUPPL. 1, 1998, Pages 3-9

  Drew, R H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIMICROBIAL THERAPY; CONFERENCE PAPER; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE DELIVERY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; REIMBURSEMENT; TREATMENT PLANNING; UNITED STATES;

EID: 0031691236     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-4453(98)92677-9     Document Type: Article

References (58)

1. Conley J, Low DE. Intravenous to oral antibiotic stepdown therapy: improving the quality of care and reducing costs. Can J Infect Dis 1995; 50: 62-72.
2. Louis TJ. Intravenous to oral stepdown antiobiotic therapy: another cost-effective strategy in an era of shrinking health care dollars. Can J Infect Dis 1994; 5: 45C-50C.
3. Burke JD, Ahkee S, Ritter GW, Ramirez JA. Development of an interdisciplinary antimicrobial team: elements for success. Hosp Pharm 1996; 31: 361-366.
4. Boyter AC, Davey PG, Hudson SA, Clark RA, Lipworth BJ. Evaluation of an antibiotic prescribing protocol for treatment of acute exacerbations of chronic obstructive airways disease in a hospital respiratory unit. J Antimicrob Chemother 1995; 36: 403-409.
5. Hunter KA, Dormaier GK. Pharmacist-managed intravenous to oral step-down program. Clin Ther 1995; 17: 534-540; discussion 516.
6. Okpra AU, Maswoswe JJ, Stewart K. Criteria-based antimicrobial IV to oral conversion programs. Formulary 1995; 30: 343-348.
7. Ramirez JA. Switch therapy in adult patients with pneumonia. Clin Pulm Med 1995; 2: 327-333.
8. Ehrenkranz NJ, Nerenberg DE, Slater KC, Shultz JM. Intervention to discontinue parenteral antimicrobial therapy in hospitalized patients with urinary tract infection, skin and soft tissue infection, or no evident infection. Infect Control Hosp Epidemiol 1993; 14: 517-522.
9. Ehrenkranz NJ, Nerenberg DE, Shultz JM, Slater KC. Intervention to discontinue parenteral antimicrobial therapy in patients hospitalized with pulmonary infections: effect on shortening patient stay [published erratum appears in Infect Control Hosp Epidemiol 1992 Mar; 13:136]. Infect Control Hosp Epidemiol 1992; 13: 21-32.
10. Frighetto L, Nickoloff D, Martinusen SM, Mamdani FS, Jewesson PJ. Intravenous-to-oral stepdown program: four years of experience in a large teaching hospital. Ann Pharmacother 1992; 26: 1447-1451.
11. Pinner RW, Teutsch SM, Simonsen L et al. Trends in infectious diseases mortality in the United States. JAMA 1996; 275: 189-193.
12. Goldmann DA, Weinstein RA, Wenzel RP et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. A challenge to hospital leadership. (Review). JAMA 1996; 275: 234-240.
13. Niederman MS, Bass JB, Jr., Campbell GD et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis 1993; 148: 1418-1426.
14. Campbell GD, Niederman MS, Broughton WA et al. Hospitalacquired pneumonia in adults diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies - a consensus statement (review). Am J Resp Crit Care Med 1996; 153: 1711-1725.
15. Rifenberg RP, Paladino JA, Hanson SC, Tuttle JA, Schentag JJ. Benchmark analysis of strategies hospitals use to control antimicrobial expenditures. Am J Health-System Pharm 1996; 53: 2054-2062.
16. Gould IM, Jappy B. Trends in hospital antibiotic prescribing after introduction of ale antibiotic policy. J Antimicrob Chemother 1996; 38: 895-904.
17. Rapp RP, Pomeroy C. Antimicrobial formulary control - is the glass half empty or half full. Am J Health-System Pharm 1996; 53: 2091-2092.
18. Gebhart F. Interqual moves to end the games in IV dosing. Hosp Pharm Rep 1994; 1: 48.
19. Douet C, Charpiat B, Peyramond D, Brazier JL. Oral administration versus injectable administration for the fluoroquinolones - pharmacoeconomic impact and bibliographical study (French). Therapie 1996; 51: 464-475.
20. Garrelts JC, Herrington AM. Cost-effective treatment of lower respiratory tract infections [review]. Pharmacoeconomics 1996; 10: 36-58.
21. Davey P. Pharmacoeconomics of appropriate antimicrobial use. Diagn Microbiol Infect Dis 1995; 22: 225-229.
22. Davey PG. Cost management in community-acquired lower respiratory tract infection. Am J Med 1995; 99: 20S-23S.
23. MacDonald TM. The economic evaluation of antibiotic therapy: relevance to urinary tract infection. J Antimicrob Chemother 1994; 33 (Suppl. A): 137-145.
24. Rimmer D. Third generation cephalosporins in the parenteral to oral switch. Pharmacoeconomics 1994; 5: 27-33.
25. Kerr JR, Barr JG, Smyth ET, O'Hare J, Bell PM, Callender ME. Antibiotic pharmacoeconomics: an attempt to find the real cost of hospital antibiotic prescribing. Ulster Med J 1993; 62: 50-57.
26. Levett PN, Jennings AM, Manning KS et al. Pharmacoeconomics of intravenous antibiotic use in serious infection. West Ind Med J 1995; 44: 81-84.
27. Kerr J. The antibiotic cost calculator; an expert system for global antibiotic cost calculation. Comput Methods Programs Biomed 1995; 46: 13-21.
28. Roark MK, Reed WE, Jr. Econotherapeutics. Diagn Microbiol Infect Dis 1995; 22: 209-217.
29. Kerr JR, Barr JG, Smyth ET. Computerised calculation of the true costs of antibiotic therapy. Eur J Clin Microbiol Infect Dis 1993; 12: 522-625.
30. Pestotnik SL, Classen DC, Evans RS, Burke JP. Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Ann Intern Med 1996; 124: 384-890.
31. Schentag JJ, Ballow CH, Fritz AL et al. Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory. Diagn Microbiol Infect Dis 1993; 16: 255-264.
32. Karki SD, Holden JM, Mariano E. A team approach to reduce antibiotic costs. DICP 1990; 24: 202-205.
33. Siegel RE, Halpern NA, Almenoff PL, Lee A, Cashin R, Greene JG. A prospective randomized study of inpatient IV antibiotics for community-acquired pneumonia; the optimal duration of therapy. Chest 1996; 110: 965-97.
34. Amodiogroton M, Madu A, Madu CN et al. Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia - a pharmacoeconomic analysis. Ann Pharmacother 1996; 30: 596-602.
35. Cunha BA. The antibiotic treatment of community-acquired, atypical, and nosocomial pneumonias. Med Clin North Am 1995; 79: 581-597.
36. Vogel F. Sequential therapy in the hospital management of lower respiratory infections. Am J Med 1995; 99: 14S-19S.
37. Paladino JA, Sperry HE, Backes JM et al. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med 1991; 91: 462-470.
38. Gutierrez K. Continuation of antibiotic therapy for serious bacterial infections outside of the hospital. Pediatric Annals 1996; 25: 639-645.
39. Hoppe JE. Rational prescribing of antibacterials in hospitalised children (review). Pharmacoeconomics 1996; 10: 575-593.
40. Anonymous. Hospital antibiotic control measures in the UK. Working Party of the British Society for Antimicrobial Chemotherapy. J Antimlcrob Chemother 1994; 34: 21-42.
41. Lesar TS, Briceland LL. Survey of antibiotic control policies in university-affiliated teaching institutions. Ann Pharmacother 1996; 30: 31-34.
42. Schmid JP, Regamey C. Proposal for a shortened i.v. antibiotic treatment as cost-saving measure in the treatment of uncomplicated infection. Schweiz Med Wochenschr 1994; 124: 2229-2233.
43. Ramirez JA, Srinath L, Ahkee S, Huang A, Raff MJ. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155: 1273-1276.
44. Lee J, Carlson JA. Chamberlain MA. A team approach to hospital formulary replacement. Diagn Microbiol Infect Dis 1995; 22: 239-242.
45. North D. Controlling the costs of antibiotic resistance. Clin Ther 1993; 15 (Suppl. A): 3-11.
46. Quintiliani R, Nightingale CH, Crowe HM, Cooper BW, Bartlett RC, Gousse G. Strategic antibiotic decision-making at the formulary level. (Review). Rev Infect Dis 1991; 13 (Suppl. 9): S770-777.
47. Ramirez JA. Switch therapy in community-acquired pneumonia. Diagn Microbiol Infect Dis 1995; 22: 219-223.
48. Weingarten SR, Riedinger MS, Varis G et al. Identification of lowrisk hospitalized patients with pneumonia. Implications for early conversion to oral antimicrobial therapy. Chest 1994; 105: 1109-1115.
49. Sanders WE, Morris JF, Alessi P et al. Oral ofloxacin in the treatment of acute bacterial pneumonia: use of a nontraditional protocol to compare experimental therapy with "usual care" in a multicenter clinical trial. Am J Med 1991; 91: 261-266.
50. Greenberg RN, Tice AD, Marsh PK et al. Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis. Am J Med 1987; 82: 266-269.
51. Hodson ME, Butland RJA, Roberts CM, Smith MJ, Batten JC. Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adult patients with cystic fibrosis. Lancet 1987; i: 235-237.
52. Cornelissen JJ Rozenberg-Arska M, Dekker AW. Discontinuation of intravenous antibiotic therapy during persistent neutropenia in patients receiving prophylaxis with oral ciprofloxacin. Clin Infect Dis 1997; 21: 1300-1302.
53. Freifeld AG, Pizzo PA. The outpatient management of febrile neutropenia in cancer patients. Oncology 1996; 10: 599-612.
54. Horowitz HW, Holmgren D, Seiter K. Stepdown single event antibiotic therapy for the management of the high risk neutropenic adult with hematologic malignancies. Leuk Lymphom 1996; 23: 159-163.
55. Rolston KVI. Outpatients management of fever in neutropenic patients. Curr Opin Infect Dis 1996; 9: 407-410.
56. Bow EJ, Loewen R, Vaughan D. Reduced requirement for antibiotic therapy targeting gram-negative organisms in febrile, neutropenic patients with cancer who are receiving antibacterial chemoprophylaxis with oral quinolones. Clin Infect Dis 1995; 20: 907-912.
57. Malik IA, Abbas Z, Karim M. Randomized comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 1992; 339: 1092-1096.
58. Caceres VM, Stange KC, Kikano GE, Zyzanski SJ. The clinical utility of a day of hospital observation after switching from intravenous to oral antibiotic therapy in the treatment of pyelonephritis. J Fam Pract 1994; 39: 337-339.